抗体偶联药物在胰腺癌治疗中的研究进展  

Advances of antibody drug conjugates in pancreatic cancer therapy

作　　者：李泓璇 王莹[1] 王菊仙[1] LI Hong-xuan;WANG Ying;WANG Ju-xian(Institute of Medicinal Biotechnology,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China)

机构地区：[1]中国医学科学院、北京协和医学院,医药生物技术研究所,北京100050

出　　处：《药学学报》2024年第10期2697-2708,共12页Acta Pharmaceutica Sinica

基　　金：中国医学科学院医学与健康科技创新工程项目(2021-1-I2M-026)。

摘　　要：胰腺癌是致命的恶性肿瘤之一,现有的手术切除和化疗手段均未能很好地改善患者的预后情况,因此亟需寻找更安全有效的治疗方法以满足临床治疗需求。抗体偶联药物(antibody drug conjugate,ADC)是一类利用化学连接子将单克隆抗体与小分子细胞毒药物偶联而成的靶向抗肿瘤药物,具有选择性高、效力高、毒副作用低等优势。近年来,ADC在多种肿瘤治疗中的成功应用掀起了抗胰腺癌ADC的研究热潮。本文就ADC的结构和作用机制及其在抗胰腺癌领域中的研究现状作一综述,为今后抗胰腺癌ADC的研究提供一定的参考依据。Pancreatic cancer is one of the most lethal malignant tumors.While the existing surgical resection and chemotherapy have failed to improve the prognosis of patients well,it is urgent to find safer and more effective therapies to meet the clinical therapeutic needs.Antibody drug conjugate(ADC)is a class of targeted antitumor agents that combines monoclonal antibodies with small molecule cytotoxic drugs via chemical linkers.ADC provided wider therapeutic windows and enhanced pharmacokinetic/pharmacodynamic properties which depended on their characteristics of high selectivity,high efficacy and low toxicity.In recent years,the successful application of ADC in the treatment of multiple tumors has aroused a research upsurge in ADC for pancreatic cancer.This review summarizes the structure and mechanism of ADC and the current status of ADC for pancreatic cancer in order to provide some references for the future development of ADC for pancreatic cancer.

关 键 词：抗体偶联药物 胰腺癌 靶点 连接子 有效载荷 

分 类 号：R966[医药卫生—药理学]